Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
MWN-AI** Summary
Bioxytran, Inc., a biotechnology company focused on carbohydrate-based therapeutics, has entered a Sponsored Research Agreement with the University of Minnesota to advance its biochemical research capabilities. The partnership, directed by Dr. Kevin Mayo, an expert in biomolecular structure, aims to deepen the understanding of polysaccharide and oligosaccharide interactions with critical biological targets. This collaboration is pivotal for Bioxytran, as CEO David Platt emphasized, solidifying the scientific foundation of the company’s carbohydrate technology platform.
The research will utilize advanced nuclear magnetic resonance (NMR) spectroscopy to analyze how specific carbohydrate structures interact with target molecules relevant to biological systems. Findings from this research could significantly influence Bioxytran’s development strategies and preclinical initiatives across various biomedical fields. Additionally, the academic-industry collaboration reflects a synergistic approach to tackle complex scientific challenges, with the University ensuring adherence to scientific rigor and policies.
The research program is slated to run until early 2027, with structured milestones and progress reviews. Bioxytran will finance research personnel and necessary laboratory resources, while intellectual property developed will remain under the University’s ownership, granting Bioxytran extensive rights to the research data for its internal use.
This collaboration is part of a broader strategy by Bioxytran to enhance scientific validation and strengthen academic alliances, positioning itself at the forefront of innovation in carbohydrate technologies. The University of Minnesota, renowned for its significant contributions to biomedical research, serves as an ideal partner for translating fundamental scientific discoveries into practical applications. As Bioxytran continues to evolve its drug development efforts, this partnership is foundational in unlocking new therapeutic pathways and fostering advancements in glycovirology and degenerative disease treatments.
MWN-AI** Analysis
Bioxytran, Inc. (OTCQB: BIXT), with its recent Sponsored Research Agreement with the University of Minnesota, is strategically positioning itself in a lucrative market focused on carbohydrate-based therapeutics. This collaboration brings scientific rigor and advanced methodologies such as nuclear magnetic resonance (NMR) spectroscopy to explore polysaccharide interactions, potentially accelerating the development of innovative treatments in glycovirology and degenerative diseases.
Investors should take note of several strategic advantages this partnership presents. First, Bioxytran's focus on carbohydrate-based drug design aligns with increasing investments in biotechnology that leverage biomolecular interactions to develop novel therapeutics. The partnership with a reputable academic institution enhances Bioxytran's credibility and may facilitate access to additional funding and collaborative opportunities.
Moreover, Dr. Kevin Mayo’s expertise signifies a robust research design and execution framework, which is crucial for producing data that investors can be confident in. The potential intellectual property generated during this collaboration could significantly enhance Bioxytran’s asset portfolio, offering pathways for future commercialization of innovative therapeutic solutions.
As Bioxytran advances its research through to early 2027, periodic progress reports will be vital for maintaining investor confidence. Observing the outcomes of these studies, especially relating to binding interactions and structural conformations of carbohydrates, will be crucial for assessing the viability of its research and development pipeline.
However, potential investors must stay aware of the inherent risks in biotech investments—especially the dependency on research outcomes and regulatory approvals. It is advisable to keep an eye on Bioxytran’s milestones and ensure alignment with the broader trends in the biotech sector. In summary, BIXT presents a promising opportunity for investors looking to engage with a company at the forefront of carbohydrate-based therapeutic research, provided they remain cognizant of the associated risks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.
Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.
“This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”
Research Focus
The sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.
Academic–Industry Collaboration
The agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.
"This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”
Timeline and Structure
The research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.
Strategic Significance
For Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.
About the University of Minnesota
The University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.
About Bioxytran, Inc.
Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.
Company Contact
Bioxytran, Inc.
75 Second Avenue, Needham, MA 02494
Phone: 617?454?1199
Email: info@Bioxytraninc.com
Web: www.Bioxytraninc.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10?K for the year ended December 31, 2024.
FAQ**
How does the Sponsored Research Agreement between Bioxytran Inc BIXT and the University of Minnesota aim to enhance the company's carbohydrate-based technology platform and its development pipeline?
What specific milestones and progress reviews are outlined in the research collaboration between Bioxytran Inc BIXT and Dr. Kevin Mayo's team at the University of Minnesota?
In what ways does Bioxytran Inc BIXT plan to leverage the research findings from this collaboration to inform future preclinical initiatives and therapeutic applications?
What are the potential commercial implications for Bioxytran Inc BIXT resulting from the intellectual property generated through the University of Minnesota's research on polysaccharides and oligosaccharides?
**MWN-AI FAQ is based on asking OpenAI questions about Bioxytran Inc (OTC: BIXT).
NASDAQ: BIXT
BIXT Trading
-5.3% G/L:
$0.05 Last:
60,500 Volume:
$0.0528 Open:
